Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04932005 · ClinicalTrials.gov registry record · Phase 1
A Study of DZD2269 in Healthy Adult Participants
A Phase 1 study, sponsored by Dizal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT04932005 is a Phase 1 study that has completed, run by Dizal Pharmaceuticals. The registered enrollment target is 72 participants.
The verdict
NCT04932005, a Phase 1 study, has completed, sponsored by Dizal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a research study in healthy participants. The purpose of this study is to see how safe the study drug is and how well it is tolerated after dosing. This study will also investigate pharmacokinetics of DZD2269; renal excretion of DZD2269 will also be evaluated. The study will also measure biomarkers such as pCREB in the blood.
Interventions
- DRUG placebo
- DRUG DZD2269
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2022-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04932005
The ClinicalTrials.gov registry entry for NCT04932005 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dizal Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT04932005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04932005 about?
NCT04932005 is a clinical study titled "A Study of DZD2269 in Healthy Adult Participants". This is a research study in healthy participants. The purpose of this study is to see how safe the study drug is and how well it is tolerated after dosing. This study will also investigate pharmacokinetics of DZD2269; renal excretion of DZD2269 will also be evaluated. The study will also measure bio...
What is the current status of trial NCT04932005?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2021-06-29. Estimated completion is 2022-04-12.
What interventions are being tested in trial NCT04932005?
The interventions under investigation include: placebo (DRUG), DZD2269 (DRUG).
Who is sponsoring clinical trial NCT04932005?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.